In this issue:
Drug survival of omalizumab for CSU
CSU after COVID-19 mRNA vaccine
Risk of cancer with urticaria
Remibrutinib for CSU
LIBERTY-CSU CUPID: dupliumab for CSU
Leukotriene antagonist + antihistamines for CSU
Mast cell & basophil inhibition with remibrutinib in vitro
Burden of non-skin-related symptoms in CSU
Please login below to download this issue (PDF)